Imiquimod 5% cream for the treatment of actinic keratosis: Results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials

Journal of the American Academy of Dermatology

Volumn 50, Issue 5, 2004, Pages 714-721

  Lebwohl, Mark ^a   Dinehart, Scott ^b,c   Whiting, David ^d   Lee, Peter K ^e   Tawfik, Naji ^f,g   Jorizzo, Joseph ^h   Lee, James H ⁱ   Fox, Terry L ⁱ  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c B G P D/Sangster Dermatol   (United States)

^d Dallas Associated Dermatologists   (United States)

^e University of Minnesota   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Welborn Clinic Research Center   (United States)

^h WAKE FOREST SCHOOL OF MEDICINE   (United States)

ⁱ 3M COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRY SKIN; EDEMA; ERYTHEMA; FEMALE; FLU LIKE SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCALP; SIDE EFFECT; SKIN BURNING SENSATION; SKIN CANCER; SKIN IRRITATION; TREATMENT OUTCOME; UNITED STATES;

EID: 2342450044     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2003.12.010     Document Type: Article

References (14)

1. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol 1994;131:455-64.
2. Heaphy MRJ, Ackerman AB. The nature of solar keratosis: a critical review in historical perspective. J Am Acad Dermatol 2000; 43:138-50.
3. Coldiron BM. Thinning of the ozone layer: facts and consequences. J Am Acad Dermatol 1992;27:653-62.
4. Engel A, Johnson M-L, Haynes SG. Health effects of sunlight exposure in the United States: results from the first national health and nutrition examination survey 1971-1974. Arch Dermatol 1988;124:72-9.
5. Frost CA, Green AC, Williams GM. The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia). Br J Dermatol 1998;139:1033-9.
6. Ponsford MW, Goodman G, Marks R. The prevalence and accuracy of diagnosis of non-melanotic skin cancer in Victoria. Australas J Dermatol 1983;24:79-82.
7. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000;42(Suppl):S8-10.
8. Stockfleth E, Meyer T, Benninghoff B, Salasche S, Papadopoulos L, Ulrich C, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002;138:1498-502.
9. Stockfleth E, Meyer T, Benninghoff B, Christophers E. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. Br J Dermatol 2001;144:1050-3.
10. Persaud AN, Shamuelova E, Sherer D, Lou W, Singer G, Cervera C, et al. Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. J Am Acad Dermatol 2002;47:553-6.
11. Salasche S, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol 2002;47:571-7.
12. Aberer W, Shuler G, Stingl G, Hunigsmann H, Wolff K. Ultraviolet light depletes surface markers of Langerhans cells. J Invest Dermatol 1981;76:202-7.
13. Strickland F, Kripke M. Immune response associated with non-melanoma skin cancer. Clin Plast Surg 1997;24:637-47.
14. Tucci M, Offidani A, Lucarini G, Simonelli L, Amati S, Cellini A, et al. Advances in the understanding of malignant transformation of keratinocytes: an immunohistochemical study. J Eur Acad Dermatol Venereol 1998;10:118-24.